Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Weinstein

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Arthritis Research & Therapy|September 13, 2008
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusRichard Furie, William Stohl, Ellen M Ginzler, et al.
Journal of Medical Ethics|November 25, 2010
Scientific evidence and best patient care practices should guide the ethics of Lyme disease activismPaul G Auwaerter, Johan S Bakken, Raymond J Dattwyler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 20, 2008
Differential expression and molecular associations of Syk in systemic lupus erythematosus T cellsSandeep Krishnan, Yuang-Taung Juang, Bhabadeb Chowdhury, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2019
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus ErythematosusRosalind Ramsey-Goldman, Roberta Vezza Alexander, Elena M Massarotti, et al.
ACR Open Rheumatology|February 4, 2021
A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified LupusRosalind Ramsey-Goldman, Roberta Vezza Alexander, John Conklin, et al.
Arthritis and Rheumatism|August 29, 2009
Novel evidence-based systemic lupus erythematosus responder indexRichard A Furie, Michelle A Petri, Daniel J Wallace, et al.
Lupus Science & Medicine|October 9, 2019
Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLEDaniel J Wallace, Roberta Vezza Alexander, Tyler O'Malley, et al.
The Journal of Rheumatology|November 5, 2013
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusEllen M Ginzler, Daniel J Wallace, Joan T Merrill, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
The Lancet. Infectious Diseases|August 27, 2011
Antiscience and ethical concerns associated with advocacy of Lyme diseasePaul G Auwaerter, Johan S Bakken, Raymond J Dattwyler, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Arthritis Research & Therapy|September 13, 2008
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusRichard Furie, William Stohl, Ellen M Ginzler, et al.
Journal of Medical Ethics|November 25, 2010
Scientific evidence and best patient care practices should guide the ethics of Lyme disease activismPaul G Auwaerter, Johan S Bakken, Raymond J Dattwyler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 20, 2008
Differential expression and molecular associations of Syk in systemic lupus erythematosus T cellsSandeep Krishnan, Yuang-Taung Juang, Bhabadeb Chowdhury, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2019
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus ErythematosusRosalind Ramsey-Goldman, Roberta Vezza Alexander, Elena M Massarotti, et al.
ACR Open Rheumatology|February 4, 2021
A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified LupusRosalind Ramsey-Goldman, Roberta Vezza Alexander, John Conklin, et al.
Arthritis and Rheumatism|August 29, 2009
Novel evidence-based systemic lupus erythematosus responder indexRichard A Furie, Michelle A Petri, Daniel J Wallace, et al.
Lupus Science & Medicine|October 9, 2019
Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLEDaniel J Wallace, Roberta Vezza Alexander, Tyler O'Malley, et al.
The Journal of Rheumatology|November 5, 2013
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusEllen M Ginzler, Daniel J Wallace, Joan T Merrill, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
The Lancet. Infectious Diseases|August 27, 2011
Antiscience and ethical concerns associated with advocacy of Lyme diseasePaul G Auwaerter, Johan S Bakken, Raymond J Dattwyler, et al.
Pageof 5